Quantum量子訊息有限公司
← 最新全球產業報告

Infantile Spasm Treatment Market

研究執行與發布:Coherent Market Insights · 發布日期 2026-01-28 · 151 頁
由量子訊息有限公司(Quantum Information)在台灣代理銷售與提供授權諮詢。

2026 年市場規模
USD 1.08 Bn
2033 年預估規模
USD 1.67 Bn
年複合成長率 CAGR
4.1%

以上數字由 Coherent Market Insights 於本報告中提出,量子訊息原樣引用。

出版商 Coherent Market Insights產業別 Healthcare & Life Sciences出版日期 2026-01-28頁數 151報告編號 CMI2453

授權報價

Single User Price$4,500 USD
Enterprise License$10,000 USD
洽詢購買 申請 Sample
完整報告名稱與涵蓋範圍
Infantile Spasm Treatment Market, By Product Type (Adrenocorticotropic Hormone, Vigabatrin, and Phase III), By Route of Administration (Oral and Parenteral), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

報告摘要

Infantile spasm is a rare disorder that appears as seizures in infants below 1 year. Infantile spasm causes series of sudden, jerking movements of legs and arms or fast drop of head. The duration of spasm can last up to couple of seconds. Major drugs used for the treatment of infantile spasm include adrenocorticotropic hormone (ACTH), however, due to its side effects, doctors also prefer anti-seizure drugs such as vigabatrin and other steroid therapies. Market Dynamics Increasing prevalence of central nervous system infection, may develop infantile spasm which in turn is expected to boost the infantile spasm treatment market. According to the National Center for Biotechnology Information (NCBI), in January 2018, the prevalence of infantile spasm was 2 to 3.5 infants per 10,000 live births. Government initiatives for rare disease treatment is expected to boost the market growth. For instance, The American Academy of Pediatrics also works with the Child Neurology Society, Child Neurology Foundation, American College of Emergency Physicians, and other partners to build advocacy, identify awareness gaps, and expand outreach opportunities. The relapse or reoccurrence of infantile spasm is a major factor driving growth of the infantile spasm treatment market. According to investigators from Okayama University Hospital, Japan, after the treatment of infantile spasm with ACTH therapy for 11 to 37 days, the disease reoccurred in 41% of the people under study. Moreover, the government of Brazil in year 2017 amended its regulatory rules for approving drugs for rare disease. In December 2017, Brazilian regulatory agency, Agência Nacional de Vigilância Sanitária (ANVISA) published Resolution RDC 205/2017, regulating special procedures for clinical trials, registration, and certification of Good Manufacturing Practices (GMPs) of drugs intended to treat, prevent or diagnose rare diseases such as infantile spasm. Key features of the study • This report provides in-depth analysis of the infantile spasm treatment market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global infantile spasm treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans • Key companies covered as a part of this study include H. Lundbeck A/S, Mallinckrodt Pharmaceuticals, Catalyst Pharmaceuticals, GW Pharmaceuticals plc, Retrophin, Inc., Valerion Therapeutics, Orphelia Pharma SA, Insys Therapeutics, Inc., and Anavex Life Sciences Corp. • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics • The global infantile spasm treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the infantile spasm treatment market Market Segmentation • By Product Type o Adrenocorticotropic Hormone o Vigabatrin o Phase III • By Route of Administration o Oral o Parenteral • By Regional Insights o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o Lundbeck A/S o Mallinckrodt Pharmaceuticals o Catalyst Pharmaceuticals o GW Pharmaceuticals plc o Retrophin, Inc. o Valerion Therapeutics o Orphelia Pharma SA o Insys Therapeutics, Inc. o Anavex Life Sciences Corp.
目錄 Table of Contents
Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Market Snippet, By Product Type  Market Snippet, By Route of Administration  Market Snippet, By Region o Coherent Opportunity Map (COM) 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics  Drivers  Restraints  PEST Analysis  PORTER’s Five Forces Analysis  Market Opportunities  Regulatory Scenario  Key Developments  Industry Trend 4. Global Infantile Spasm Treatment Market , By Product Type, 2026-2033, (USD Bn) o Introduction  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Adrenocorticotropic Hormone  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Vigabatrin  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Phase III  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends 5. Global Infantile Spasm Treatment Market , By Route of Administration, 2026-2033, (USD Bn) o Introduction  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Oral  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Parenteral  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends 6. Global Infantile Spasm Treatment Market , By Region, 2026-2033, (USD Bn) o Introduction  Market Share Analysis, By Region, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, For Region, 2021 - 2033 o North America  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)  Market Size and Forecast, By Route of Administration, 2026- 2033, (USD Bn)  Market Size and Forecast, By Country, 2026- 2033, (USD Bn) o U.S. o Canada o Latin America  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)  Market Size and Forecast, By Route of Administration, 2026- 2033, (USD Bn)  Market Size and Forecast, By Country, 2026- 2033, (USD Bn) o Brazil o Argentina o Mexico o Rest of Latin America o Europe  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)  Market Size and Forecast, By Route of Administration, 2026- 2033, (USD Bn)  Market Size and Forecast, By Country, 2026- 2033, (USD Bn) o U.K. o Germany o Italy o France o Spain o Russia o Rest of Europe o Asia Pacific  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)  Market Size and Forecast, By Route of Administration, 2026- 2033, (USD Bn)  Market Size and Forecast, By Country, 2026- 2033, (USD Bn) o China o India o Japan o ASEAN o Australia o South Korea o Rest of Asia Pacific o Middle East  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)  Market Size and Forecast, By Route of Administration, 2026- 2033, (USD Bn)  Market Size and Forecast, By Country, 2026- 2033, (USD Bn) o GCC Countries o Israel o Rest of Middle East o Africa  Market Share Analysis, By Country/Region, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country/Region, 2021 - 2033  Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)  Market Size and Forecast, By Route of Administration, 2026- 2033, (USD Bn)  Market Size and Forecast, By Country, 2026- 2033, (USD Bn) o South Africa o North Africa o Central Africa 7. Competitive Landscape o Heat Map Analysis o Market Share Analysis (3x3 Matrix) o Company Profiles  H. Lundbeck A/S o Company Overview o Product Type Portfolio o Recent Developments/Updates  Mallinckrodt Pharmaceuticals o Company Overview o Product Type Portfolio o Recent Developments/Updates  Catalyst Pharmaceuticals o Company Overview o Product Type Portfolio o Recent Developments/Updates  GW Pharmaceuticals plc o Company Overview o Product Type Portfolio o Recent Developments/Updates  Retrophin, Inc. o Company Overview o Product Type Portfolio o Recent Developments/Updates  Valerion Therapeutics o Company Overview o Product Type Portfolio o Recent Developments/Updates  Orphelia Pharma SA o Company Overview o Product Type Portfolio o Recent Developments/Updates  Insys Therapeutics, Inc. o Company Overview o Product Type Portfolio o Recent Developments/Updates  Anavex Life Sciences Corp. o Company Overview o Product Type Portfolio o Recent Developments/Updates 8. Analyst Recommendation o Wheel of Fortune o Analyst View o Coherent Opportunity Map 9. Section o References o Research Methodology o About Us and Sales Contact

提及公司

Lundbeck A/SMallinckrodt PharmaceuticalsCatalyst PharmaceuticalsGW Pharmaceuticals plcRetrophin, Inc.Valerion TherapeuticsOrphelia Pharma SAInsys Therapeutics, Inc.Anavex Life Sciences Corp.

同分類最新報告(醫療與生命科學)

常見問題

這份報告可以先索取樣本嗎?

可以。建議購買前先申請樣本,提出申請後約 2 個工作天內提供,您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算?

報告以美元標價,台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本(單人/多人/企業全站)價格不同,量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付?如何付款?

一般 3–7 個工作天交付,實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票,30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理,提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們